Beneficial effects of mineralocorticoid receptor blockade in experimental non-alcoholic steatohepatitis

Liver International

Volumn 35, Issue 9, 2015, Pages 2129-2138

  Pizarro, Margarita ^a   Solís, Nancy ^a   Quintero, Pablo ^a   Barrera, Francisco ^a   Cabrera, Daniel ^a,b   Rojas de Santiago, Pamela ^a   Arab, Juan P ^a   Padilla, Oslando ^a   Roa, Juan C ^a   Moshage, Han ^c   Wree, Alexander ^d   Inzaugarat, Eugenia ^d   Feldstein, Ariel E ^d   Fardella, Carlos E ^a   Baudrand, Rene ^a   Riquelme, Arnoldo ^a   Arrese, Marco ^a  

^a PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

^b UNIVERSIDAD BERNARDO O'HIGGINS   (Chile)

^c UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^d UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

Fatty liver; Fibrosis; Inflammation; NASH; Steatohepatitis

Indexed keywords

ALANINE AMINOTRANSFERASE; ALDOSTERONE; AMINO ACID; ASPARTATE AMINOTRANSFERASE; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; CHOLINE; COLLAGEN 1 ALPHA 1; COLLAGEN ALPHA 1; COLLAGEN TYPE 3; COLLAGEN TYPE III ALPHA 1; EPLERENONE; GELATINASE A; GLUTATHIONE REDUCTASE; GLUTATHIONE REDUCTASE 1; GLUTATHIONE SYNTHASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; LIPOPOLYSACCHARIDE; MONOCYTE CHEMOTACTIC PROTEIN 1; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TRANSCRIPTION FACTOR NRF2; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; MINERALOCORTICOID ANTAGONIST; MINERALOCORTICOID RECEPTOR; SPIRONOLACTONE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL SUBPOPULATION; CONTROLLED STUDY; DIET; DISSE SPACE; EXPERIMENTAL DIGESTIVE SYSTEM DISEASE; GENE EXPRESSION; HEPATITIS; IMMUNOHISTOCHEMISTRY; KUPFFER CELL; LIVER CELL; LIVER FIBROSIS; LIVER INJURY; LIVER WEIGHT; MALE; MOUSE; NONALCOHOLIC FATTY LIVER; NONHUMAN; OXIDATIVE STRESS; PROTEIN EXPRESSION; STELLATE CELL; UPREGULATION; WEIGHT GAIN; ANALOGS AND DERIVATIVES; ANIMAL; C57BL MOUSE; DISEASE MODEL; GENETICS; LIVER; LIVER CIRRHOSIS; METABOLISM; NON-ALCOHOLIC FATTY LIVER DISEASE; PATHOLOGY;

ANIMALS; BIOMARKERS; DISEASE MODELS, ANIMAL; LIVER; LIVER CIRRHOSIS; MALE; MICE; MICE, INBRED C57BL; MINERALOCORTICOID RECEPTOR ANTAGONISTS; NON-ALCOHOLIC FATTY LIVER DISEASE; OXIDATIVE STRESS; RECEPTORS, MINERALOCORTICOID; SPIRONOLACTONE;

EID: 84938987660     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.12794     Document Type: Article

References (41)

1. Lomonaco R, Sunny NE, Bril F, Cusi K. Nonalcoholic fatty liver disease: current issues and novel treatment approaches. Drugs 2013; 73: 1-14.
2. Brunt EM. Pathology of nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol 2010; 7: 195-203.
3. Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther 2011; 34: 274-85.
4. Riquelme A, Arrese M, Soza A, et al. Non-alcoholic fatty liver disease and its association with obesity, insulin resistance and increased serum levels of C-reactive protein in Hispanics. Liver Int 2009; 29: 82-8.
5. Boza C, Riquelme A, Ibanez L, et al. Predictors of nonalcoholic steatohepatitis (NASH) in obese patients undergoing gastric bypass. Obes Surg 2005; 15: 1148-53.
6. Machado MV, Goncalves S, Carepa F, et al. Impaired renal function in morbid obese patients with nonalcoholic fatty liver disease. Liver Int 2012; 32: 241-8.
7. Rahimi RS, Landaverde C. Nonalcoholic fatty liver disease and the metabolic syndrome: clinical implications and treatment. Nutr Clin Pract 2013; 28: 40-51.
8. Anstee QM, Targher G, Day CP. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nat Rev Gastroenterol Hepatol 2013; 10: 330-44.
9. Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology 2012; 142: 1592-609.
10. Angulo P. Long-term mortality in nonalcoholic fatty liver disease: is liver histology of any prognostic significance? Hepatology 2010; 51: 373-5.
11. Schuppan D, Kim YO. Evolving therapies for liver fibrosis. J Clin Investig 2013; 123: 1887-901.
12. Viengchareun S, Le Menuet D, Martinerie L, et al. The mineralocorticoid receptor: insights into its molecular and (patho)physiological biology. Nucl Recept Signal 2007; 5: e012.
13. Fujisawa G, Muto S, Okada K, Kusano E, Ishibashi S. Mineralocorticoid receptor antagonist spironolactone prevents pig serum-induced hepatic fibrosis in rats. Transl Res 2006; 148: 149-56.
14. Candia R, Riquelme A, Baudrand R, et al. Overexpression of 11beta-hydroxysteroid dehydrogenase type 1 in visceral adipose tissue and portal hypercortisolism in non-alcoholic fatty liver disease. Liver Int 2012; 32: 392-9.
15. Tarantino G, Finelli C. Pathogenesis of hepatic steatosis: the link between hypercortisolism and non-alcoholic fatty liver disease. World J Gastroenterol 2013; 19: 6735-43.
16. Wada T, Miyashita Y, Sasaki M, et al. Eplerenone ameliorates the phenotypes of metabolic syndrome with NASH in liver-specific SREBP-1c Tg mice fed high-fat and high-fructose diet. Am J Physiol Endocrinol Metab 2013; 305: E1415-25.
17. Karagiannis A, Athyros VG, Mikhailidis DP. A comparison of the aldosterone-blocking agents eplerenone and spironolactone. Clin Cardiol 2009; 32: 230.
18. Miura K, Kodama Y, Inokuchi S, et al. Toll-like receptor 9 promotes steatohepatitis by induction of interleukin-1beta in mice. Gastroenterology 2010; 139: 323-34.
19. Hirata A, Maeda N, Hiuge A, et al. Blockade of mineralocorticoid receptor reverses adipocyte dysfunction and insulin resistance in obese mice. Cardiovasc Res 2009; 84: 164-72.
20. Carr TP, Andresen CJ, Rudel LL. Enzymatic determination of triglyceride, free cholesterol, and total cholesterol in tissue lipid extracts. Clin Biochem 1993; 26: 39-42.
21. Ibanez P, Solis N, Pizarro M, et al. Effect of losartan on early liver fibrosis development in a rat model of nonalcoholic steatohepatitis. J Gastroenterol Hepatol 2007; 22: 846-51.
22. Seki E, De Minicis S, Osterreicher CH, et al. TLR4 enhances TGF-beta signaling and hepatic fibrosis. Nat Med 2007; 13: 1324-32.
23. Kodama Y, Kisseleva T, Iwaisako K, et al. c-Jun N-terminal kinase-1 from hematopoietic cells mediates progression from hepatic steatosis to steatohepatitis and fibrosis in mice. Gastroenterology 2009; 137: 1467-77.
24. Marra F, Lotersztajn S. Pathophysiology of NASH: perspectives for a targeted treatment. Curr Pharm Des 2013; 19: 5250-69.
25. Ucar F, Sezer S, Erdogan S, et al. The relationship between oxidative stress and nonalcoholic fatty liver disease: its effects on the development of nonalcoholic steatohepatitis. Redox Rep 2013; 18: 127-33.
26. Guo C, Ricchiuti V, Lian BQ, et al. Mineralocorticoid receptor blockade reverses obesity-related changes in expression of adiponectin, peroxisome proliferator-activated receptor-gamma, and proinflammatory adipokines. Circulation 2008; 117: 2253-61.
27. Hirata A, Maeda N, Nakatsuji H, et al. Contribution of glucocorticoid-mineralocorticoid receptor pathway on the obesity-related adipocyte dysfunction. Biochem Biophys Res Commun 2012; 419: 182-7.
28. Conn JW. Hypertension, the potassium ion and impaired carbohydrate tolerance. N Engl J Med 1965; 273: 1135-43.
29. Fallo F, Veglio F, Bertello C, et al. Prevalence and characteristics of the metabolic syndrome in primary aldosteronism. J Clin Endocrinol Metab 2006; 91: 454-9.
30. Omori Y, Mano T, Ohtani T, et al. Glucocorticoids induce cardiac fibrosis via mineralocorticoid receptor in oxidative stress: contribution of elongation factor eleven-nineteen lysine-rich leukemia (ELL). Yonago Acta Med 2014; 57: 109-16.
31. Lieber GB, Fernandez X, Mingo GG, et al. Mineralocorticoid receptor antagonists attenuate pulmonary inflammation and bleomycin-evoked fibrosis in rodent models. Eur J Pharmacol 2013; 718: 290-8.
32. Nielsen FT, Jensen BL, Hansen PB, Marcussen N, Bie P. The mineralocorticoid receptor antagonist eplerenone reduces renal interstitial fibrosis after long-term cyclosporine treatment in rat: antagonizing cyclosporine nephrotoxicity. BMC Nephrol 2013; 14: 42.
33. Cabrera D, Pizarro M, Solis N, et al. Effects of andrographolide in experimental non-alcoholic steatohepatitis. Hepatology 2013; 58: 547A.
34. Lim HY, Muller N, Herold MJ, van den Brandt J, Reichardt HM. Glucocorticoids exert opposing effects on macrophage function dependent on their concentration. Immunology 2007; 122: 47-53.
35. Smyth GP, Stapleton PP, Freeman TA, et al. Glucocorticoid pretreatment induces cytokine overexpression and nuclear factor-kappaB activation in macrophages. J Surg Res 2004; 116: 253-61.
36. Baudrand R, Carvajal CA, Riquelme A, et al. Overexpression of 11beta-hydroxysteroid dehydrogenase type 1 in hepatic and visceral adipose tissue is associated with metabolic disorders in morbidly obese patients. Obes Surg 2010; 20: 77-83.
37. Luo P, Dematteo A, Wang Z, et al. Aldosterone deficiency prevents high-fat-feeding-induced hyperglycaemia and adipocyte dysfunction in mice. Diabetologia 2013; 56: 901-10.
38. Usher MG, Duan SZ, Ivaschenko CY, et al. Myeloid mineralocorticoid receptor controls macrophage polarization and cardiovascular hypertrophy and remodeling in mice. J Clin Investig 2010; 120: 3350-64.
39. Bienvenu LA, Morgan J, Rickard AJ, et al. Macrophage mineralocorticoid receptor signaling plays a key role in aldosterone-independent cardiac fibrosis. Endocrinology 2012; 153: 3416-25.
40. De Minicis S, Agostinelli L, Rychlicki C, et al. HCC development is associated to peripheral insulin resistance in a mouse model of NASH. PLoS One 2014; 9: e97136.
41. Marzolla V, Armani A, Feraco A, et al. Mineralocorticoid receptor in adipocytes and macrophages: a promising target to fight metabolic syndrome. Steroids 2014; 91: 46-53.